LBA-002Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). (24th June 2018) - Tabernero, J; Shitara, K; Dvorkin, M; Mansoor, W; Arkenau, H T; Prokharau, A; Alsina, M; Ghidini, M; Faustino, C; Gorbunova, V; Zhavrid, E; Nishikawa, K; et al.